Abstract
The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.
| Original language | English |
|---|---|
| Pages (from-to) | 335-348 |
| Number of pages | 14 |
| Journal | Critical Reviews in Oncology/Hematology |
| Volume | 97 |
| DOIs | |
| Publication status | Published - Jan 1 2016 |
Fingerprint
Keywords
- Anti-angiogenic
- Bevacizumab
- Front-line
- Ovarian cancer
- Phase III
- Vascular endothelial growth factor
ASJC Scopus subject areas
- Oncology
- Hematology
- Geriatrics and Gerontology
Cite this
Bevacizumab in ovarian cancer : Focus on clinical data and future perspectives. / Colombo, Nicoletta; Conte, Pierfranco; Pignata, Sandro; Raspagliesi, Francesco; Scambia, Giovanni.
In: Critical Reviews in Oncology/Hematology, Vol. 97, 01.01.2016, p. 335-348.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bevacizumab in ovarian cancer
T2 - Focus on clinical data and future perspectives
AU - Colombo, Nicoletta
AU - Conte, Pierfranco
AU - Pignata, Sandro
AU - Raspagliesi, Francesco
AU - Scambia, Giovanni
PY - 2016/1/1
Y1 - 2016/1/1
N2 - The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.
AB - The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.
KW - Anti-angiogenic
KW - Bevacizumab
KW - Front-line
KW - Ovarian cancer
KW - Phase III
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=84952638192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952638192&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2015.08.017
DO - 10.1016/j.critrevonc.2015.08.017
M3 - Article
VL - 97
SP - 335
EP - 348
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -